Thomas A. Ciulla

Dr. Ciulla has served as our Chief Medical Officer and Chief Development Officer since March 2020. He joined Clearside as Chief Medical Officer in October 2018. Prior to joining Clearside, Dr. Ciulla served a VP role, as Medical Strategy Lead-Ophthalmology at Spark Therapeutics, where he defined and led medical strategy to support the development and commercialization of Luxturna (voretigene neparvovec-rzyl), the first FDA-approved gene therapy for a genetic disease. He previously served a VP role, in Clinical Strategy at Ophthotech Corporation.

Before launching his executive management career, Dr. Ciulla co-directed the retina service and ocular angiogenesis research lab at Indiana University School of Medicine, the largest U.S. med school. He remains a volunteer Clinical Professor at the university and serves on the Board of Directors of Midwest Eye Institute. He is an active member of the American Society of Gene and Cell Therapy, the Association for Research in Vision and Ophthalmology, the Macula Society, the Retina Society, the American Society of Retina Specialists, and the American Academy of Ophthalmology.